İkbal Ok Bozkaya

ORCID: 0000-0002-7666-8731
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Hematopoietic Stem Cell Transplantation
  • Acute Lymphoblastic Leukemia research
  • Acute Myeloid Leukemia Research
  • Childhood Cancer Survivors' Quality of Life
  • Neonatal Respiratory Health Research
  • Neonatal Health and Biochemistry
  • Cytomegalovirus and herpesvirus research
  • Hemoglobinopathies and Related Disorders
  • Iron Metabolism and Disorders
  • Blood transfusion and management
  • Blood disorders and treatments
  • Hematological disorders and diagnostics
  • Immunodeficiency and Autoimmune Disorders
  • Bone and Joint Diseases
  • Epilepsy research and treatment
  • COVID-19 Clinical Research Studies
  • Environmental and Sediment Control
  • Mesenchymal stem cell research
  • Blood groups and transfusion
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Hemophilia Treatment and Research
  • Mechanical Circulatory Support Devices
  • Autoimmune and Inflammatory Disorders Research
  • Platelet Disorders and Treatments

Memorial Ankara Hospital
2011-2024

Sağlık Bilimleri Üniversitesi
2017-2024

Pediatrics and Genetics
2024

Bilkent University
2023-2024

Ankara Bilkent City Hospital
2023-2024

University of Health Sciences Antigua
2023

Ankara Mevki Asker Hastanesi
2023

Ministry of Health
2012-2022

University of Health Science
2021

University of Health Sciences
2021

Abstract Purpose Deficiency of adenosine deaminase 2 (DADA2) is an inherited inborn error immunity, characterized by autoinflammation (recurrent fever), vasculopathy (livedo racemosa, polyarteritis nodosa, lacunar ischemic strokes, and intracranial hemorrhages), immunodeficiency, lymphoproliferation, immune cytopenias, bone marrow failure (BMF). Tumor necrosis factor (TNF-α) blockade the treatment choice for vasculopathy, but often fails to reverse refractory cytopenia. We aimed study...

10.1007/s10875-021-01098-0 article EN cc-by Journal of Clinical Immunology 2021-07-29

Abstract This study retrospectively analyzed the outcomes of 61 pediatric patients with inborn errors immunity (IEI) who underwent hematopoietic stem cell transplantation (HSCT) between 2011 and 2023. Patients were categorized into primary immunodeficiency disorders (PIDD), immune dysregulation (PIRD), congenital defects phagocyte number or function (CDP). Median ages at diagnosis HSCT 9 30 months, respectively. With a median follow‐up 51 overall survival (OS) was 70%, 100‐day...

10.1111/sji.13431 article EN Scandinavian Journal of Immunology 2025-01-01

Granulocyte colony stimulating factor (G-CSF) is sometimes administered to donors before bone marrow (BM) harvest. G-CSF-primed (G-BM) and unprimed BM (U-BM)-derived mesenchymal stem cells (MSC) were obtained from 16 healthy expanded in vitro. Their proliferative characteristics, morphology, differentiation capacity examined. Supernatants of the second passage MSCs evaluated for transforming growth β1, hepatocyte factor, prostaglandin E2 (PGE2) levels compared with controls. The analyses...

10.1016/j.bbmt.2015.08.007 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2015-08-08

Ankaferd blood stopper (ABS) is a standardized medicinal plant extract that stimulates the formation of an encapsulated protein network provides focal points for erythrocyte aggregation. It has therapeutic potential to be used management external hemorrhage. Here, authors report infant bleeding from peptic ulcer was stopped successfully by gastroscopic application ABS and other cases topical mucosal bleedings are also presented.

10.3109/08880018.2010.503337 article EN Pediatric Hematology and Oncology 2010-09-23

Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most frequent cause of post-transplantation mortality. Isolated extramedullary (EM) relapse (iEMR) HSCT is relatively rare and not well characterized, particularly in pediatric patients. We retrospectively analyzed 1527 consecutive patients with acute leukemia allo-HSCT to study incidence, risk factors, outcome iEMR compared systemic relapse. The 5-year cumulative incidence (either bone marrow [BM] only...

10.1016/j.jtct.2021.06.023 article EN cc-by-nc-nd Transplantation and Cellular Therapy 2021-06-30

To date, there has been no effective treatment to prevent brain damage in premature infants or the development of post-hemorrhagic hydrocephalus (PHH) after severe intraventricular hemorrhage (IVH). Therefore, new, safe and methods need be developed improve prognosis IVH, for which morbidity mortality rates are high. Recent studies have shown that strong immunomodulatory properties mesenchymal stem cells (MSCs) an anti-inflammatory effect inhibiting PHH decreasing apoptosis gliosis, thus...

10.5137/1019-5149.jtn.34850-21.2 article EN Turkish Neurosurgery 2021-01-01

Bozkaya, Ikbal Ok; Yarali, NeSE MD; Sac, Rukiye Ünsal Tavil, Betül Kara, Abdurrahman Azik, Fatih Tunç, Bahattin PhD Author Information

10.1097/mph.0b013e31820db7d7 article EN Journal of Pediatric Hematology/Oncology 2012-04-01

Objective: In this study, we aimed to compare the effect(s) of zinc sulphate on growth and serum iron variables when it is given with ferrous in deficiency anemia (IDA). Materials Methods: Patients (n=79) were randomly divided into two groups.In one group (n=40) 4 mg/kg/d sulfate was orally.In other (n=39), addition sulfate, 5 mg/d oral given.Results: Compared initial values statistically significant increase mean height, weight, head circumference has been observed both groups after 3...

10.4274/tjh.2012.0043 article EN cc-by-nc-nd Turkish Journal of Hematology 2013-06-05

We examined outcomes of 51 pediatric patients with relapsed acute leukemia (AL) who underwent a second allogeneic hematopoietic stem cell transplantation (alloHSCT). After median follow-up 941 days (range, 69–2842 days), leukemia-free survival (LFS) and overall (OS) at 3 years were 26.6% 25.6%, respectively. The nonrelapse mortality rate (NMR) cumulative incidence relapse (CIR) 36.4% 42.4%, Cox regression analysis demonstrated that the risk factors for predicting limited LFS active disease...

10.1080/10428194.2020.1716220 article EN Leukemia & lymphoma/Leukemia and lymphoma 2020-02-08

Congenital amegakaryocytic thrombocytopenia (CAMT) generally begins at birth with severe and progresses to pancytopenia. It is caused by mutations in the thrombopoietin receptor gene, myeloproliferative leukemia virus oncogene (c-MPL). The association between CAMT c-MPL mutation type has been reported literature. Patients have categorized according their clinical symptoms different mutations. Missense of classified as II these patients delayed onset bone marrow failure compared I patients....

10.4274/tjh.2013.0191 article TR Turkish Journal of Hematology 2015-05-14

Pneumatosis cystoides intestinalis (PCI) is a disorder in which widespread air sacs are present mucosa, submucosa, subserosa, and intraabdominal area of the intestinal wall. It has heterogeneous clinical presentation as rare complication graft-versus-host disease (GVHD). Computed tomography preferred imaging method for diagnosis. Since could be ruptured spontaneously, presence free peritoneal cavity does not confirm perforation. The conservative treatment approach sufficient cases that do...

10.1111/petr.14136 article EN Pediatric Transplantation 2021-09-10

Abstract Background We aimed to evaluate our pediatric HSCT recipients routinely monitored for adenoviremia and determine the adequacy of this monitoring in predicting adenoviral disease (AD). Methods A retrospective cohort patients who underwent allogeneic between January 2021 August 2022, by real‐time PCR was included survey. Demographic clinical data were recorded. Incidence rates, risk factors, mortality rates related adenoviremia, AD analyzed. Results Among 104 HSCTs performed 94...

10.1111/petr.14696 article EN Pediatric Transplantation 2024-01-26

Data on the risk factors and outcomes for pediatric patients with SARS-CoV-2 infection (COVID-19) following hematopoietic stem cell transplantation (HSCT) are limited. The study aimed to analyze clinical signs, factors, ICU admission mortality in a large cohort who underwent allogeneic HSCT prior COVID-19 infection. In this nationwide study, we retrospectively reviewed data of 184 recipients had between March 2020 August 2022. median time from was 209.0 days (IQR, 111.7-340.8; range, 0-3845...

10.1111/petr.14758 article EN Pediatric Transplantation 2024-04-24

Abstract Background The published experience concerning autologous peripheral blood stem cell collection in children is very limited. Methods data of pediatric patients who underwent mobilization and apheresis between January 2011 April 2020 were analyzed retrospectively. Results We studied retrospectively 64 procedures 48 (34 males, 14 females), mean age 7.31 ± 5.38 (range, 1.5–19.7) years, the underlying disease was mostly neuroblastoma (NBL). body weight 21 (43.75%) 15 kg or less....

10.1111/petr.14751 article EN Pediatric Transplantation 2024-04-24

Background/aimTransfusion of blood products is a life-saving clinical practice in patients with bleeding, hemoglobinopathy and cancer. In this study, we aimed to analyze the frequency types component-related acute transfusion reactions (ATR) pediatric patients.Materials methodsThis retrospective study was conducted at tertiary care academic hospital.ResultsDuring period, 30,811 transfusions were administered 25,448 patients. 103 ATRs detected 81 (0.33%; 3.34 per 1000 transfusions, mean age...

10.55730/1300-0144.5869 article EN cc-by TURKISH JOURNAL OF MEDICAL SCIENCES 2024-10-18

ABSTRACT Hematopoietic stem cell transplantation is a curative therapy for pediatric patients with malignancies and blood or immune system disorders. However, recipients are at risk of opportunistic infections, including cytomegalovirus infection, due to immunosuppression from conditioning regimens. This retrospective study analyzed 439 hematopoietic identify factors infection assess the impact Significant included graft source, versus host disease, pre‐transplant clinically significant...

10.1002/jmv.70093 article EN Journal of Medical Virology 2024-11-01
Coming Soon ...